Pharmaceutical market opportunity assessment
Dean & Company was engaged by Diffusion Pharmaceuticals, a private clinical-stage pharmaceutical company, to conduct a market opportunity assessment of two indications for its lead product candidate, trans sodium crocetinate (TSC).
TSC is a small-molecule drug that enhances oxygen diffusion to oxygen-deprived (hypoxic) tissues. Its potential therapeutic applications include:
- Critical/Acute Care: Trauma, hemorrhage, stroke, heart attack
- Chronic Care: Cardiovascular disease, respiratory disorders, peripheral vascular disease (PAD)
- Oncology: Sensitization of tumors for radiation therapy
Our objective for the project was to determine and articulate the market opportunity of the drug for potential investors by leveraging our familiarity with the investment community from our private equity experience.
We quickly set out our plan which included three targeted methods. First we worked to profile the diseases that this drug could help to treat. Our second step was to analyze the competitive landscape for these classes of drugs and therapeutic indications. Finally, we worked to benchmark the pricing of the various treatment options currently available.
Dean & Company estimated the peak annual U.S. market opportunity for TSC to be $200MM+ for the radio-sensitization indication and over $800MM+ for the PAD indication. We then used the market opportunity analysis to develop investor presentations to support Diffusion Pharmaceuticals’ financing efforts. Additionally, Dean & Company helped Diffusion Pharmaceuticals articulate the regulatory, competitive, and commercial challenges facing the drug, and proposed several approaches to address these challenges.